Berking, C.; Livingstone, E.; Debus, D.; Loquai, C.; Weichenthal, M.; Leiter, U.; Kiecker, F.; Mohr, P.; Eigentler, T.K.; Remy, J.;
et al. COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers 2023, 15, 4436.
https://doi.org/10.3390/cancers15184436
AMA Style
Berking C, Livingstone E, Debus D, Loquai C, Weichenthal M, Leiter U, Kiecker F, Mohr P, Eigentler TK, Remy J,
et al. COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers. 2023; 15(18):4436.
https://doi.org/10.3390/cancers15184436
Chicago/Turabian Style
Berking, Carola, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy,
and et al. 2023. "COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma" Cancers 15, no. 18: 4436.
https://doi.org/10.3390/cancers15184436
APA Style
Berking, C., Livingstone, E., Debus, D., Loquai, C., Weichenthal, M., Leiter, U., Kiecker, F., Mohr, P., Eigentler, T. K., Remy, J., Schober, K., Heppt, M. V., von Wasielewski, I., Schadendorf, D., & Gutzmer, R.
(2023). COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers, 15(18), 4436.
https://doi.org/10.3390/cancers15184436
